Semaglutide vs Tirzepatide: Which Weight Loss Peptide Is Better?
Last updated: April 14, 2026 · 16 min read · Reviewed by Grey Peptides Editorial Board
TL;DR
Tirzepatide produces greater average weight loss than semaglutide in clinical trials (22.5% vs 14.9% body weight at maximum doses), primarily because it acts on two receptors (GLP-1 and GIP) rather than one (GLP-1 only). However, semaglutide has a longer track record, more published safety data, proven cardiovascular benefits (SELECT trial), and wider insurance coverage. Both are prescription medications requiring medical supervision. The "better" choice depends on how much weight you need to lose, your metabolic profile (tirzepatide shows superior glucose control), your tolerance for GI side effects, cost/insurance coverage, and your physician's recommendation.
→ Compare these peptides on 12 metrics in our Comparison Tool.
→ Estimate protocol costs with our Cost-Per-Protocol Calculator.
Table of Contents
- The Core Difference
- Head-to-Head: Clinical Trial Data
- Quick Comparison Table
- Mechanism of Action (How Each Works)
- Dosing & Titration
- Weight Loss Results
- Metabolic Benefits Beyond Weight
- Side Effects Compared
- Cardiovascular Data
- Cost & Insurance
- Which One Should You Choose?
- Can You Switch Between Them?
- Frequently Asked Questions
- Sources
The Core Difference
The fundamental distinction is pharmacological: semaglutide activates one receptor, tirzepatide activates two.
Semaglutide is a GLP-1 receptor agonist. It mimics a single gut hormone (GLP-1) to reduce appetite, slow gastric emptying, and improve insulin sensitivity.
Tirzepatide is a dual GLP-1/GIP receptor agonist. It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously. This dual action appears to produce greater metabolic effects than GLP-1 agonism alone — particularly for fat loss and glucose control.
Everything else that differs between the two compounds — the magnitude of weight loss, the side effect profile, the metabolic improvements — flows from this core pharmacological distinction.
Head-to-Head: Clinical Trial Data
No published head-to-head trial comparing semaglutide 2.4 mg directly against tirzepatide 15 mg for obesity exists yet. What we have instead is a comparison of their respective pivotal trials, which used similar designs and endpoints but enrolled different patient populations.
The SURMOUNT-5 trial (reported in 2024) did compare tirzepatide directly against semaglutide for obesity — making it the only direct comparison. Results confirmed tirzepatide's superiority: participants on tirzepatide 15 mg lost approximately 20.2% of body weight compared to 13.7% on semaglutide 2.4 mg over 72 weeks.
For type 2 diabetes, the SURPASS-2 trial compared tirzepatide directly against semaglutide 1 mg (the diabetes dose, not the higher obesity dose). All three tirzepatide doses (5 mg, 10 mg, 15 mg) produced greater HbA1c reduction and weight loss than semaglutide 1 mg.
Quick Comparison Table
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Brand names | Ozempic (diabetes), Wegovy (obesity) | Mounjaro (diabetes), Zepbound (obesity) |
| Mechanism | GLP-1 agonist (single receptor) | GLP-1 + GIP dual agonist (two receptors) |
| Max dose | 2.4 mg/week (Wegovy) | 15 mg/week (Zepbound) |
| Avg weight loss (obesity trials) | 14.9% (STEP 1) | 22.5% (SURMOUNT-1) |
| Direct comparison | 13.7% (SURMOUNT-5) | 20.2% (SURMOUNT-5) |
| HbA1c reduction | ~1.5% (diabetes dose) | ~2.1% (diabetes dose) |
| GI side effects | ~44% nausea incidence | ~31% nausea incidence |
| CV outcome data | Yes (SELECT trial — 20% MACE reduction) | Pending (SURPASS-CVOT ongoing) |
| FDA approved for obesity | Yes (Wegovy, 2021) | Yes (Zepbound, 2023) |
| Oral formulation | Yes (Rybelsus, for diabetes) | In development |
| Typical monthly cost (US) | $1,000–1,350 | $1,000–1,060 |
| Generic/biosimilar | Expected ~2031 | Expected ~2034+ |
| Time on market | Since 2017 (Ozempic) | Since 2022 (Mounjaro) |
→ Run a full detailed comparison with additional metrics in the Comparison Tool.
Mechanism of Action (How Each Works)
Semaglutide: The GLP-1 Specialist
Semaglutide is a modified version of human GLP-1 engineered for a half-life of approximately 7 days (natural GLP-1 breaks down in 2–3 minutes). It achieves three key effects through the GLP-1 receptor:
Appetite suppression. GLP-1 receptors in the hypothalamus and brainstem regulate satiety signaling. Semaglutide activates these receptors to reduce hunger and food cravings. Users consistently describe the effect as "food noise" disappearing — the constant background preoccupation with food simply quiets.
Delayed gastric emptying. Food moves more slowly through the stomach, extending the feeling of fullness after meals. This reduces meal sizes naturally.
Improved insulin signaling. GLP-1 receptor activation enhances glucose-dependent insulin secretion and suppresses glucagon release, improving blood sugar control.
Tirzepatide: The Dual Agonist
Tirzepatide is a single molecule engineered to activate both the GLP-1 receptor and the GIP receptor. The GLP-1 component produces the same effects described above. The addition of GIP agonism introduces several further mechanisms:
Enhanced fat metabolism. GIP receptors are present on adipocytes (fat cells). GIP signaling appears to improve fat tissue insulin sensitivity and may enhance lipid mobilization from fat stores, though the precise mechanisms are still being elucidated.
Superior glucose control. The dual receptor activation produces greater insulin sensitivity and HbA1c reduction than GLP-1 agonism alone. This was demonstrated clearly in the SURPASS trials, where tirzepatide consistently outperformed semaglutide on glycemic endpoints.
Potentially better GI tolerance. While this seems counterintuitive (two receptor pathways vs one), tirzepatide's nausea rates in clinical trials were actually lower than semaglutide's. GIP receptor activation may have a moderating effect on the GI slowing caused by GLP-1, though this remains an area of active research.
Additive weight loss. The combination of GLP-1's appetite suppression with GIP's metabolic effects produces greater total weight reduction than either pathway alone. This additive pharmacology is the most likely explanation for tirzepatide's superior weight loss outcomes.
Dosing & Titration
Both medications use a slow dose-escalation approach to minimize GI side effects.
Semaglutide (Wegovy)
| Week | Dose | Frequency |
|---|---|---|
| 1–4 | 0.25 mg | Weekly |
| 5–8 | 0.5 mg | Weekly |
| 9–12 | 1.0 mg | Weekly |
| 13–16 | 1.7 mg | Weekly |
| 17+ | 2.4 mg | Weekly (maintenance) |
Time to full dose: 16 weeks minimum.
Tirzepatide (Zepbound)
| Week | Dose | Frequency |
|---|---|---|
| 1–4 | 2.5 mg | Weekly |
| 5–8 | 5 mg | Weekly |
| 9–12 | 7.5 mg | Weekly |
| 13–16 | 10 mg | Weekly |
| 17–20 | 12.5 mg | Weekly |
| 21+ | 15 mg | Weekly (maintenance) |
Time to full dose: 20 weeks minimum.
Key difference: Tirzepatide has a longer titration schedule with more dose steps, allowing finer adjustment to balance efficacy against tolerability. Some patients achieve satisfactory results at intermediate doses (10 mg or 12.5 mg) without needing the maximum 15 mg.
Both are injected subcutaneously once per week. Same day each week, any time of day, with or without food.
Weight Loss Results
Semaglutide (STEP Trial Program)
| Trial | Population | Duration | Mean Weight Loss | ≥20% Loss |
|---|---|---|---|---|
| STEP 1 | Obesity without diabetes | 68 weeks | 14.9% | ~33% |
| STEP 2 | Obesity with T2D | 68 weeks | 9.6% | ~18% |
| STEP 3 | Obesity + behavioral therapy | 68 weeks | 16.0% | ~36% |
| STEP 5 | Obesity (2-year) | 104 weeks | ~15% maintained | ~36% |
Tirzepatide (SURMOUNT Trial Program)
| Trial | Population | Duration | Mean Weight Loss | ≥20% Loss |
|---|---|---|---|---|
| SURMOUNT-1 | Obesity without diabetes | 72 weeks | 22.5% (15 mg) | ~40% |
| SURMOUNT-2 | Obesity with T2D | 72 weeks | 14.7% (15 mg) | ~30% |
| SURMOUNT-3 | Obesity + lifestyle | 72 weeks | 26.6% (max dose) | ~56% |
| SURMOUNT-4 | Maintenance study | 88 weeks | Regain on withdrawal | — |
Direct Comparison (SURMOUNT-5)
| Drug | Weight Loss at 72 Weeks |
|---|---|
| Semaglutide 2.4 mg | 13.7% |
| Tirzepatide 15 mg | 20.2% |
| Difference | ~6.5 percentage points |
Bottom line: Tirzepatide produces approximately 40–50% more relative weight loss than semaglutide when both are used at maximum doses. However, individual responses vary significantly — some patients lose more weight on semaglutide, and some reach satisfactory results at tirzepatide's lower doses.
Metabolic Benefits Beyond Weight
Weight loss is the most visible outcome, but both medications produce metabolic improvements that extend beyond the number on the scale.
Blood Sugar Control
Tirzepatide consistently shows greater HbA1c reduction than semaglutide across trials. In SURPASS-2 (the direct head-to-head in diabetes patients), tirzepatide 15 mg reduced HbA1c by 2.30% versus 1.86% for semaglutide 1 mg. For people with type 2 diabetes or prediabetes, this difference is clinically meaningful.
Blood Pressure
Both medications reduce systolic blood pressure by 4–8 mmHg on average, with no clear superiority for either compound. The reduction is largely mediated by weight loss.
Lipid Profile
Both improve triglycerides, HDL, and other lipid markers. Tirzepatide may produce modestly better triglyceride reduction, potentially related to GIP's effects on fat metabolism, but the differences are small.
Liver Fat
Both medications reduce hepatic steatosis (fatty liver). Tirzepatide has shown particularly impressive results in NASH (nonalcoholic steatohepatitis) studies, with significant reductions in liver fat content and inflammation markers.
Side Effects Compared
Gastrointestinal Effects
GI side effects are the primary concern with both medications and the most common reason for dose adjustment or discontinuation.
| Side Effect | Semaglutide (Wegovy trials) | Tirzepatide (Zepbound trials) |
|---|---|---|
| Nausea | 44% | 31% |
| Diarrhea | 30% | 23% |
| Vomiting | 24% | 13% |
| Constipation | 24% | 12% |
| Discontinuation due to AEs | ~7% | ~6% |
Tirzepatide has a meaningfully lower incidence of GI side effects across all categories. This is one of its more surprising advantages given that it activates an additional receptor. The lower GI burden may be because GIP receptor activation partially counteracts the gastric-slowing effects of GLP-1, or because the titration schedule allows more gradual dose increases.
Other Side Effects
Both medications carry similar warnings for pancreatitis (rare), gallbladder events (more common at higher weight loss), and a theoretical thyroid risk (C-cell tumors in rodents, not confirmed in humans). Injection site reactions are mild and similar for both.
Muscle Loss Concern
Both medications can cause lean mass loss alongside fat loss when caloric deficit is aggressive. Studies suggest 25–40% of weight lost can be lean mass. This is not specific to either medication — it occurs with any large caloric deficit — but it emphasizes the importance of resistance training and adequate protein intake during treatment with either compound.
Cardiovascular Data
This is currently semaglutide's most significant advantage.
Semaglutide: The SELECT trial (2023) demonstrated a 20% reduction in major adverse cardiovascular events (MACE — heart attack, stroke, cardiovascular death) in people with obesity and established cardiovascular disease. This was a landmark finding — the first time a weight management medication showed direct cardiovascular benefit. This data led to Wegovy receiving an expanded FDA indication for cardiovascular risk reduction.
Tirzepatide: The SURPASS-CVOT trial is still ongoing. No published cardiovascular outcome data exists yet for tirzepatide. While the metabolic improvements (weight loss, glucose control, blood pressure reduction) strongly suggest cardiovascular benefit, it hasn't been proven in a dedicated outcomes trial.
For patients with established cardiovascular disease, semaglutide's proven MACE reduction is a significant differentiator that tirzepatide cannot currently match.
Cost & Insurance
List Prices (US, 2026)
| Medication | Brand (Obesity) | Monthly List Price |
|---|---|---|
| Semaglutide | Wegovy | ~$1,350/month |
| Tirzepatide | Zepbound | ~$1,060/month |
Insurance Coverage
Coverage varies dramatically by insurer and plan. Semaglutide (Wegovy/Ozempic) generally has broader insurance coverage because it has been on the market longer and has the cardiovascular indication. Tirzepatide (Zepbound/Mounjaro) coverage is expanding but less established.
Medicare currently does not cover anti-obesity medications, though legislative efforts to change this are ongoing.
Compounded Versions
Compounded semaglutide has been available at significantly lower cost ($150–400/month) through compounding pharmacies. However, FDA enforcement against compounding of tirzepatide and semaglutide is evolving as brand supply shortages resolve. Check current regulatory status before pursuing compounded options.
→ Estimate your total protocol costs including bloodwork with the Cost-Per-Protocol Calculator.
Which One Should You Choose?
This decision should be made with your prescribing physician, but here's a framework for thinking about it.
Consider semaglutide if:
- You have established cardiovascular disease (proven MACE reduction)
- You prefer a medication with a longer safety track record
- Your insurance covers Wegovy/Ozempic but not Zepbound/Mounjaro
- You want the option of an oral formulation (Rybelsus, diabetes dose)
- You're achieving satisfactory results — 15% weight loss is significant for most people
Consider tirzepatide if:
- You need maximum weight loss (BMI >40, or prior inadequate response to GLP-1 only)
- You have type 2 diabetes and need superior glucose control
- You're concerned about GI side effects (lower incidence with tirzepatide)
- You didn't respond adequately to semaglutide
- Your insurance covers Zepbound/Mounjaro
Either medication is appropriate if:
- You have obesity without diabetes and need substantial weight reduction
- You don't have established cardiovascular disease
- Both are covered by your insurance or you're paying out-of-pocket
Can You Switch Between Them?
Yes, switching is common in clinical practice. The most frequent scenario is switching from semaglutide to tirzepatide when weight loss plateaus or GI side effects are limiting further dose escalation.
Switching tips:
- Discuss timing with your prescriber — typically switch directly at the next scheduled dose
- When switching from semaglutide 2.4 mg to tirzepatide, most physicians start at tirzepatide 5 mg (not the beginner 2.5 mg dose) since you've already adapted to GLP-1 receptor activation
- Expect an adjustment period — different GI side effect profile despite overlapping mechanism
- Weight loss typically resumes or accelerates after the switch, particularly if you had plateaued
Frequently Asked Questions
Is tirzepatide "better" than semaglutide? For weight loss and glucose control, tirzepatide produces superior results on average. For cardiovascular risk reduction, semaglutide has proven outcomes data that tirzepatide lacks. For GI tolerability, tirzepatide has lower side effect rates. Neither is universally "better" — the best choice depends on your specific clinical situation.
Do they work the same way? They overlap significantly — both activate the GLP-1 receptor. The key difference is that tirzepatide additionally activates the GIP receptor, which appears to enhance fat metabolism and glucose control beyond what GLP-1 agonism alone achieves.
Will I regain weight after stopping either one? Yes — both medications are associated with significant weight regain after discontinuation. The STEP 1 extension and SURMOUNT-4 studies both demonstrated that weight returns when treatment stops. This positions both as chronic treatments, not short-term interventions.
Can I use these with peptides like BPC-157 or CJC-1295/Ipamorelin? GLP-1 agonists are prescription medications and should only be combined with other compounds under medical supervision. There are no published interaction studies between GLP-1 agonists and research peptides. Discuss any combination with your prescribing physician.
Which has fewer side effects? Tirzepatide has lower reported rates of nausea, vomiting, diarrhea, and constipation in clinical trials. However, individual responses vary — some people tolerate semaglutide better. The slow titration schedule for both is designed to minimize GI impact.
Is there something even more effective coming? Retatrutide (a triple GLP-1/GIP/glucagon agonist) showed 24.2% weight loss in Phase 2 and is in Phase 3 trials. Amycretin, CagriSema, and survodutide are other next-generation candidates. All are still investigational.
Related Tools & Articles
- Comparison Tool — Full 12-metric comparison of semaglutide vs tirzepatide
- Cost-Per-Protocol Calculator — Estimate monthly costs
- Best Peptides for Fat Loss 2026 — All weight loss peptides ranked
- Are Peptides Legal? 2026 Guide — Regulatory status
Sources
- Wilding, J. P. H. et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 384(11), 989–1002. PMID: 33567185
- Jastreboff, A. M. et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 387(3), 205–216. PMID: 35658024
- Frías, J. P. et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine, 385(6), 503–515. PMID: 34170647
- Lincoff, A. M. et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine, 389(24), 2221–2232. PMID: 37952131
- Aronne, L. J. et al. (2024). Tirzepatide vs semaglutide for treatment of obesity (SURMOUNT-5). New England Journal of Medicine. PMID: 39652474
- Wadden, T. A. et al. (2023). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). Lancet, 402(10402), 693–704. PMID: 37385280
- Wilding, J. P. H. et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 extension). Diabetes, Obesity and Metabolism, 24(8), 1553–1564. PMID: 35441470
- Aronne, L. J. et al. (2024). Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA, 331(1), 38–48. PMID: 38078870
Medical Disclaimer: This article is for educational and informational purposes only. Semaglutide and tirzepatide are prescription medications that require medical supervision. This comparison is not a recommendation for or against either medication. Always consult a licensed healthcare provider for personalized medical advice.
© 2026 GreyPeptides.com — All rights reserved.
This article is for educational purposes only and does not constitute medical advice. Consult a licensed medical professional before considering any peptide therapy.